GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

GSK highlighted clinical data from its oncology pipeline at the European Society for Medical Oncology meeting, covering B7-H3 ADC ris-rez, B7-H4 ADC mo-rez, PD-1 therapy dostarlimab and ROS1 inhibitor JIDEYTRO. The article provides no specific trial results or numerical data to assess their clinical or commercial implications.